Cas:872005-48-6 Lumogen Red F300 manufacturer & supplier

Chemical Name:Lumogen Red F300

CAS.NO:872005-48-6

Synonyms:MFCD11111420;Isoquino[4′,5′,6′:6,5,10]anthra[2,1,9-def]isoquinoline-1,3,8,10(2H,9H)-tetrone, 5,6,12,13-tetrakis[4-(1,1-dimethylethyl)phenoxy]-2,9-dioctyl-;5,6,12,13-Tetrakis[4-(2-methyl-2-propanyl)phenoxy]-2,9-dioctylisoquinolino[4′,5′,6′:6,5,10]anthra[2,1,9-def]isoquinoline-1,3,8,10(2H,9H)-tetrone

Molecular Formula:C₈₀H₉₀N₂O₈

Molecular Weight:1207.58

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.2±0.0 g/cm3

Index of Refraction:1.619

PSA:

Exact Mass:1206.670044

LogP:24.03

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD11111420 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5,6,12,13-Tetrakis[4-(2-methyl-2-propanyl)phenoxy]-2,9-dioctylisoquinolino[4′,5′,6′:6,5,10]anthra[2,1,9-def]isoquinoline-1,3,8,10(2H,9H)-tetrone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5,6,12,13-Tetrakis[4-(2-methyl-2-propanyl)phenoxy]-2,9-dioctylisoquinolino[4′,5′,6′:6,5,10]anthra[2,1,9-def]isoquinoline-1,3,8,10(2H,9H)-tetrone Use and application,5,6,12,13-Tetrakis[4-(2-methyl-2-propanyl)phenoxy]-2,9-dioctylisoquinolino[4′,5′,6′:6,5,10]anthra[2,1,9-def]isoquinoline-1,3,8,10(2H,9H)-tetrone technical grade,usp/ep/jp grade.

Related News: It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. N-(2)Naphthyl-benzimidsaeure-chlorid manufacturers For these reasons, many pharmaceutical companies are choosing to evaluate biocatalytic processes during early-stage drug development to avoid missing opportunities for capitalizing on these gains. trans-7-(4-azetidin-1-yl-cyclohexyl)-5-(3-benzyloxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine suppliers Contract research organisation Charles River Laboratories International Inc. today announced plans for an €8M expansion of its testing capabilities at its Ballina, Co. Mayo site that will give an additional 1,500m2 of lab space and create up to 90 new skilled roles over the next three years. Pyrrolidine, 1-[[4-(4-oxo-1-piperidinyl)phenyl]sulfonyl]- vendor & factory The relationship between a CDMO and the company also depends on influencing aspects such as transparent communication, involvement at every step, and support while dealing with challenges. ,For these reasons, many pharmaceutical companies are choosing to evaluate biocatalytic processes during early-stage drug development to avoid missing opportunities for capitalizing on these gains.